Warfarin pharmacogenetics in patients with heart valve replacement


Bezci K., Cevik M., Akdeniz C. S. , Canbolat I. P. , Yurdakul S., SÜNBÜL M., ...Daha Fazla

GENE REPORTS, cilt.20, 2020 (ESCI İndekslerine Giren Dergi) identifier identifier

Özet

Background: Warfarin treatment is crucial to prevent thrombolytic complications after the heart valve replacement (HVR) operation. Our purpose was to investigate the prevalence of CYP2C9 *2 and *3 gene polymorphisms, which are essential in warfarin metabolism in patients with and without HVR surgery prescribed with warfarin.